Replies to post #1117 on Antares Pharma, Inc. (ATRS)

[rph_investor]

I also believe QS-M to be in-house. #3 of the 4 they've told us about. I've been racking my brain with the neurological indication. If M is what it starts with, then the most likely meds are morphine or meperidine (Demerol). I've looked through a couple of my resources. Not too many injections that would apply to neurology with an M. It may be a diversion til they get the IP protection.

[cacheflash57]

Jab are there any concerns with the QS-T market penetration? I know the injectables account for 1/3 the market. What advantage do we have with our product over the existing products and my main concern does it save any money for the insurance companies over the current injectables? Thanks